Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus.

Md Yusof MY, Britton J, Edward S, Hensor EMA, Goodfield MJ, Laws PM, Emery P, Wittmann M, Vital EM.

Lupus. 2019 Oct;28(11):1320-1328. doi: 10.1177/0961203319873977. Epub 2019 Sep 14.

2.

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature.

Shalbaf M, Alase AA, Berekmeri A, Md Yusof MY, Pistolic J, Goodfield MJ, Edward S, Botchkareva NV, Stacey M, Vital EM, Wittmann M.

Lupus Sci Med. 2019 Jul 14;6(1):e000328. doi: 10.1136/lupus-2019-000328. eCollection 2019.

3.

A striking case of dermatosis neglecta.

Bhoyrul B, Goodfield MJ, Laws PM.

Int Wound J. 2017 Dec;14(6):1409-1410. doi: 10.1111/iwj.12819. Epub 2017 Oct 9. No abstract available.

PMID:
28990328
4.

Bullous dermatosis associated with complex regional pain syndrome.

Bhoyrul B, Goodfield MJ.

Int Wound J. 2017 Dec;14(6):1395-1396. doi: 10.1111/iwj.12727. Epub 2017 Feb 28. No abstract available.

PMID:
28244249
5.

Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire.

Merola JF, Nyberg F, Furukawa F, Goodfield MJ, Hasegawa M, Marinovic B, Szepietowski J, Dutz J, Werth VP.

Lupus Sci Med. 2015 Mar 26;2(1):e000085. doi: 10.1136/lupus-2015-000085. eCollection 2015.

6.

From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013.

Schultz HY, Dutz JP, Furukawa F, Goodfield MJ, Kuhn A, Lee LA, Nyberg F, Szepietowski JC, Sontheimer RD, Werth VP.

J Invest Dermatol. 2015 Jan;135(1):7-12. doi: 10.1038/jid.2014.316. No abstract available.

7.

Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools.

Coates LC, Walsh J, Haroon M, FitzGerald O, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS.

Arthritis Care Res (Hoboken). 2014 Sep;66(9):1410-6. doi: 10.1002/acr.22284.

8.

Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors.

Coates LC, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS.

Br J Dermatol. 2014 Apr;170(4):995-6. doi: 10.1111/bjd.12824. No abstract available.

PMID:
24400977
9.

Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study).

Coates LC, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS.

Br J Dermatol. 2013 Apr;168(4):802-7. doi: 10.1111/bjd.12190. Erratum in: Br J Dermatol. 2013 Jun;168(6):1376. Burden-The, E [corrected to Burden-Teh, Esther].

PMID:
23311587
10.

Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study.

Wahie S, Daly AK, Cordell HJ, Goodfield MJ, Jones SK, Lovell CR, Carmichael AJ, Carr MM, Drummond A, Natarajan S, Smith CH, Reynolds NJ, Meggitt SJ.

J Invest Dermatol. 2011 Oct;131(10):1981-6. doi: 10.1038/jid.2011.167. Epub 2011 Jul 7.

11.

Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010.

Goodfield MJ, Cox NH, Bowser A, McMillan JC, Millard LG, Simpson NB, Ormerod AD.

Br J Dermatol. 2010 Jun;162(6):1172-9. doi: 10.1111/j.1365-2133.2010.09836.x. No abstract available.

PMID:
21250961
12.

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology.

Ormerod AD, Campalani E, Goodfield MJ; BAD Clinical Standards Unit.

Br J Dermatol. 2010 May;162(5):952-63. doi: 10.1111/j.1365-2133.2010.09755.x. Review. No abstract available.

PMID:
20423353
13.

Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis.

Rose RF, Turner D, Goodfield MJ, Goulden V.

Photodermatol Photoimmunol Photomed. 2009 Jun;25(3):153-5. doi: 10.1111/j.1600-0781.2009.00422.x.

PMID:
19438995
14.

Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin.

Rose RF, Goodfield MJ, Clark SM.

Clin Exp Dermatol. 2006 Jan;31(1):154-5. No abstract available.

PMID:
16309527
15.

Recalcitrant hand pompholyx: variable response to etanercept.

Ogden S, Clayton TH, Goodfield MJ.

Clin Exp Dermatol. 2006 Jan;31(1):145-6. No abstract available.

PMID:
16309517
16.

Isotretinoin-induced elkonyxis.

Yung A, Johnson P, Goodfield MJ.

Br J Dermatol. 2005 Sep;153(3):671-2. No abstract available.

PMID:
16120167
17.

Pityriasis rubra pilaris as the initial presentation of renal cell carcinoma?

Batchelor RJ, Yung A, Merchant W, Goodfield MJ.

Clin Exp Dermatol. 2005 Jul;30(4):442-3. No abstract available.

PMID:
15953096
18.

Objective assessment of compliance with treatments in acne.

Zaghloul SS, Cunliffe WJ, Goodfield MJ.

Br J Dermatol. 2005 May;152(5):1015-21.

PMID:
15888162
19.

Acute widespread oedema, hypoproteinaemia and generalized morphoea.

Rose RF, Goodfield MJ, Gilbey SG.

Clin Exp Dermatol. 2005 May;30(3):303-4. No abstract available.

PMID:
15807702
20.

Combining PUVA therapy with systemic immunosuppression to treat progressive diffuse morphoea.

Rose RF, Goodfield MJ.

Clin Exp Dermatol. 2005 May;30(3):226-8.

PMID:
15807674
21.

An evaluation of the role of a store-and-forward teledermatology system in skin cancer diagnosis and management.

Mahendran R, Goodfield MJ, Sheehan-Dare RA.

Clin Exp Dermatol. 2005 May;30(3):209-14.

PMID:
15807671
22.

Systemic lupus erythematosus or infection with HIV, or both?

Sommer S, Piyadigamage A, Goodfield MJ.

Clin Exp Dermatol. 2004 Jul;29(4):393-5.

PMID:
15245539
23.

Good response of linear scleroderma in a child to ciclosporin.

Strauss RM, Bhushan M, Goodfield MJ.

Br J Dermatol. 2004 Apr;150(4):790-2. No abstract available.

PMID:
15099393
24.

Objective assessment of compliance with psoriasis treatment.

Zaghloul SS, Goodfield MJ.

Arch Dermatol. 2004 Apr;140(4):408-14.

PMID:
15096368
25.

Paraneoplastic immunobullous disease with an epidermolysis bullosa acquisita phenotype: two cases demonstrating remission with treatment of gynaecological malignancy.

Chamberlain AJ, Cooper SM, Allen J, Dean D, Baxter KF, Goodfield MJ, Wojnarowska F.

Australas J Dermatol. 2004 May;45(2):136-9.

PMID:
15068465
26.

Prediction of outcome in the treatment of onychomycosis.

Sommer S, Sheehan-Dare RA, Goodfield MJ, Evans EG.

Clin Exp Dermatol. 2003 Jul;28(4):425-8.

PMID:
12823307
27.

Digital imaging in clinical dermatology across the UK in the year 2001.

Strauss RM, Goodfield MJ.

J Eur Acad Dermatol Venereol. 2003 May;17(3):285-7.

PMID:
12702066
28.

Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.

Thomson KF, Goodfield MJ.

J Dermatolog Treat. 2001 Sep;12(3):145-7.

PMID:
12243705
29.

Connective tissue disease and the skin.

Sommer S, Goodfield MJ.

Clin Med (Lond). 2002 Jan-Feb;2(1):9-14. Review. No abstract available.

30.

PUVA therapy in necrobiosis lipoidica diabeticorum.

Ling TC, Thomson KF, Goulden V, Goodfield MJ.

J Am Acad Dermatol. 2002 Feb;46(2):319-20. No abstract available.

PMID:
11807451
31.

PUVA therapy in lichen aureus.

Ling TC, Goulden V, Goodfield MJ.

J Am Acad Dermatol. 2001 Jul;45(1):145-6.

PMID:
11423854
32.

Is it useful to test for antibodies to extractable nuclear antigens in the presence of a negative antinuclear antibody on Hep-2 cells?

Thomson KF, Murphy A, Goodfield MJ, Misbah SA.

J Clin Pathol. 2001 May;54(5):413. No abstract available.

33.

Trichophyton tonsurans tinea capitis and tinea corporis: treatment and follow-up of four affected family members.

Ravenscroft J, Goodfield MJ, Evans EG.

Pediatr Dermatol. 2000 Sep-Oct;17(5):407-9.

PMID:
11085674
34.

L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis.

Sigurgeirsson B, Billstein S, Rantanen T, Ruzicka T, di Fonzo E, Vermeer BJ, Goodfield MJ, Evans EG.

Br J Dermatol. 1999 Nov;141 Suppl 56:5-14.

PMID:
10730908
35.

Treatment of superficial white onychomycosis with topical terbinafine cream.

Goodfield MJ, Evans EG.

Br J Dermatol. 1999 Sep;141(3):604-5. No abstract available.

PMID:
10583101
36.

Novel causes of contact dermatitis from offshore oil-based drilling muds.

Ormerod AD, Dwyer CM, Goodfield MJ.

Contact Dermatitis. 1998 Nov;39(5):262-3. No abstract available.

PMID:
9840270
37.

Onychomycosis and linear nail growth.

Goulden V, Goodfield MJ.

Br J Dermatol. 1997 Jan;136(1):139-40. No abstract available.

PMID:
9039321
38.

Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis.

Goulden V, Goodfield MJ.

Br J Dermatol. 1996 Aug;135(2):305-6.

PMID:
8881680
39.

Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser.

Bottomley WW, Goodfield MJ, Sheehan-Dare RA.

Br J Dermatol. 1996 Aug;135(2):302-4.

PMID:
8881679
40.

Clinical aspects of the use of gamma linolenic acid in systemic sclerosis.

Stainforth JM, Layton AM, Goodfield MJ.

Acta Derm Venereol. 1996 Mar;76(2):144-6.

41.

Hydroxychloroquine and chronic erythema nodosum.

Jarrett P, Goodfield MJ.

Br J Dermatol. 1996 Feb;134(2):373. No abstract available.

PMID:
8746362
42.

Methotrexate for the treatment of discoid lupus erythematosus.

Bottomley WW, Goodfield MJ.

Br J Dermatol. 1995 Oct;133(4):655-6. No abstract available.

PMID:
7577605
43.

Delayed hypersensitivity reaction to the preservative myristyl picolinium chloride.

Goulden V, Goodfield MJ.

Contact Dermatitis. 1995 Sep;33(3):209-10. No abstract available.

PMID:
8565476
44.

Fatal salmonellosis in systemic lupus erythematosus.

Taylor G, Goodfield MJ.

Clin Exp Dermatol. 1995 May;20(3):255-7.

PMID:
7671427
45.

Treatment of childhood dermatophyte infections with oral terbinafine.

Goulden V, Goodfield MJ.

Pediatr Dermatol. 1995 Mar;12(1):53-4.

PMID:
7792222
46.

The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration.

Ibbotson SH, Layton AM, Davies JA, Goodfield MJ.

Br J Dermatol. 1995 Mar;132(3):422-6.

PMID:
7718459
47.

Plasminogen activator inhibitor 1 (PAI-1) levels in patients with chronic venous leg ulceration.

Ibbotson SH, Layton AM, Davies JA, Goodfield MJ.

Br J Dermatol. 1994 Nov;131(5):738-9. No abstract available.

PMID:
7999621
48.

Randomised trial of oral aspirin for chronic venous leg ulcers.

Layton AM, Ibbotson SH, Davies JA, Goodfield MJ.

Lancet. 1994 Jul 16;344(8916):164-5.

PMID:
7912767
49.

The systemic effect of dithranol treatment in psoriasis.

Goodfield MJ, Hull SM, Cunliffe WJ.

Acta Derm Venereol. 1994 Jul;74(4):295-7.

50.

The skin in systemic sclerosis.

Goodfield MJ.

Clin Dermatol. 1994 Apr-Jun;12(2):229-36. Review. No abstract available.

PMID:
8076260

Supplemental Content

Loading ...
Support Center